Houston research team snags $2M grant for virus sensing tech

money moves

A team out of the engineering school at Rice University has created a technology for real-time wastewater monitoring. Photo via rice.edu

A team of researchers from Rice University have received a $2 million grant to develop a unique technology that speeds up the analysis of wastewater for viruses from hours to seconds.

The team is based out of Rice’s George R. Brown School of Engineering and led by Rafael Verduzco, associate chair and a professor of chemical and biomolecular engineering and of materials science and nanoengineering. The four-year grant from the National Science Foundation will support the development of the technology, which includes wastewater-testing bioelectric sensors that deliver immediate notice of presence of viruses like SARS-CoV-2, which causes COVID-19, according to a news release from Rice.

The research project — with its partners at the Houston Health Department — have already developed water testing procedures and have analyzed samples from locations around the city. The current process includes taking samples and transferring them to Rice for analysis, but the new technology would be able to monitor systems onsite and instantly. The parties involved with this work are also collaborating with the Centers for Disease Control and Prevention Center of Excellence for wastewater epidemiology that was announced in August.

“Monitoring wastewater for COVID has been pretty effective as a way to get an idea of where we are as a population,” says Verduzco in the release. “But the way it’s done is you have to sample it, you have to do a PCR test and there’s a delay. Our selling point was to get real-time, continuous monitoring to see just how much of this virus is in the wastewater.”

The grant's co-principal investigators include Jonathan Silberg, the Stewart Memorial Professor of BioSciences and director of the Systems, Synthetic and Physical Biology Ph.D. program, and Caroline Ajo-Franklin, a professor of biosciences. Co-investigators also include Lauren Stadler, an assistant professor of civil and environmental engineering, and Kirstin Matthews, a fellow at the Baker Institute for Public Policy.

“These are engineered microbes we’re putting into wastewater, and even though they’re encapsulated, we want to know if there are concerns from health authorities and the general population,” Verduzco said. “Kirstin’s role is to look at the policy side, and also gauge public reaction and educate people about what it means when we talk about engineered bacteria.”

Rafael Verduzco is leading the research and development. Photo by Jeff Fitlow/Rice University

For over a year now, scientists have been testing wastewater for COVID-19. Now, the public can access that information. Photo via Getty Images

City launches public dashboard for tracking COVID-19 in Houston's wastewater

data points

In 2020, a group of researchers began testing Houston's wastewater to collect data to help identify trends at the community level. Now, the team's work has been rounded up to use as an online resource.

The Houston Health Department and Rice University launched the dashboard on September 22. The information comes from samples collected from the city's 39 wastewater treatment plants and many HISD schools.

"This new dashboard is another tool Houstonians can use to gauge the situation and make informed decisions to protect their families," says Dr. Loren Hopkins, chief environmental science officer for the health department and professor in the practice of statistics at Rice University, in a news release. "A high level of virus in your neighborhood's wastewater means virus is spreading locally and you should be even more stringent about masking up when visiting public places."

The health department, Houston Water, Rice University, and Baylor College of Medicine originally collaborated on the wastewater testing. Baylor microbiologist Dr. Anthony Maresso, director of BCM TAILOR Labs, led a part of the research.

"This is not Houston's first infectious disease crisis," Maresso says in an earlier news release. "Wastewater sampling was pioneered by Joseph Melnick, the first chair of Baylor's Department of Molecular Virology and Microbiology, to get ahead of polio outbreaks in Houston in the 1960s. This work essentially ushered in the field of environmental virology, and it began here at Baylor. TAILOR Labs is just continuing that tradition by providing advanced science measures to support local public health intervention."

It's an affordable way to track the virus, says experts. People with COVID-19 shed viral particles in their feces, according to the release, and by testing the wastewater, the health department can measure important infection rate changes.

The dashboard, which is accessible online now, is color-coded by the level of viral load in wastewater samples, as well as labeled with any recent trend changes. Houstonians can find the interactive COVID-19 wastewater monitoring dashboard, vaccination sites, testing sites, and more information at houstonemergency.org/covid19.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston medtech firm secures $30M for neurosurgical robot

stroke surgery

Robotic neurosurgery is an exciting new frontier in medicine, and Houston-based medtech firm XCath is leading the charge with its revolutionary Iris robotic system. The company announced in March that it had secured $30 million in Series C funding to continue developing systems to tackle blood clots in the human brain.

“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” Eduardo Fonseca, CEO of XCath, said in a news release. “In 2025, the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”

XCath–which also has campuses in Pangyo, South Korea–has already achieved a number of remarkable firsts in robotic neurosurgery. The Iris is the only endovascular robotic system currently in development to perform intracranial navigation or neurointerventional treatment, and is the only robot in the world to have performed an intracranial neurovascular procedure involving the robotic manipulation of three devices.

These new Series C funds, which bring the company's total investment to $92 million, will go toward developing a clinical telerobot capable of performing a mechanical thrombectomy. This would bring unprecedented accuracy and precision to the surgical removal of brain clots, significantly reducing the risk of neurosurgery.

“Robotic surgery succeeds when innovation is paired with practical execution,” Dr. Fred Moll, chairman of the XCath board of directors, said in the release. “XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”

In November 2025, the Iris debuted under the control of Dr. Vitor Mendes Pereira at The Panama Clinic in Panama City, alongside local Principal Investigator Dr. Anastasio Ameijeiras Sibauste. It was only the second time in human history that a robot had been used for intracranial neurovascular intervention, and it established Iris as a viable technology in the fight against stroke.

“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems,” Nicholas Drysdale, CFO of XCath, added in the release. “With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics”.

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

View All Listings